joining quarter earnings evening, good call. Sylvia, for you, and Thank third everyone. XXXX you our Thank us all
plan third reflects continuum innovative with positioned transform medicine across continue therapies. performance to and to company of in progress quarter, strategic deliver Anika executing in are very we the our a into orthopedic commercial company's X-year regenerative We global which pleased to make products the the the
demand, in execution continued delivered discipline. team's earnings platform our the revenue to and on testament the expanding strong growth double-digit global successfully and quarter, a As Anika's growing commercial we of fiscal strength
third global For adjusted XX% strong products, for revenue innovative growing year-over-year EBITDA to our platform X%, income increased the U.S. internationally. net and as internal build of of quarter, successfully model, our the completed we launch grew leverage demand therapies and commercial total continue We of both U.S. the XX% increased under TACTOSET. our model product in and hybrid first the soft out our and that
quarter are year her and and our discuss third strong the in will our we full more Sylvia of XXXX, raising detail which performance, commentary. revenue Given guidance during for earnings update financial
is employees talented Needless continued Please I to effort, am to across I the focus say, of collaboration X. number Slide very Anika saw execution and turn the proud and from growing a team organization. our
we As last for Analyst discussed time this pivotal of our represents month, Day and the new dawn day Anika. Investor at a
is to become restoration in with technologies joint vision exceed preservation Our that customers' leader our innovative expectations. the global and
regenerative therapies U.S. the portfolio focus in and our into established joint and and development, abroad, think and foundation, strong affairs, osteoarthritis, actively regulatory Through for working strategic this commercialization. we our is manufacturing expand and are proven footprint our beyond pain evolution plan, We primary given clinical a expertise to preservation our in restoration. historical on natural our our management X-year product
opportunity, the the represents serve on to both. have fields orthopedic approximate point an regenerative an our operating are and room for global divided driven commercial products through therapies; market billion new pipeline target surgical office-based therapeutic An channels: that X segments expanded injectable by This continuum pain market It's management and note distinct call therapies. for call and X point and and to in the we $X important combined across multiple
on focused As point office-based many of call historically the partnerships have exclusively. you know, our legacy commercial
operating But to our team squarely commercial structure theater. to on the X. going channel in our valued the providing efforts, the hybrid important second we important an partner, turn to can new focused direct sales forward, Through we confident we surgical technologies room. that Slide Please become plan activate number with are
As to preservation performance. products; strategy by in X pursue growth I and focus is restoration, we our continue position Ps: driven our people; leadership our the what on and joint call
we First, skill we talent right the organization want to drive the have operational to the right and ensure sets excellence. toward that
our to drive delivering of margin model and number leveraging innovative turn continuum offerings commercial and we focused Please X. expansion. we in joint efficiencies are to are And hybrid Second, driving expanding operational our throughout the committed the across product technologies Slide on restoration developing and care. preservation to finally, business
P, the people. start with first Let's
committed to support are our transformation to to innovation we for and building and We make base sure place talent strongest to knowledge enhance that the expertise our our team's future team have continue in growth. and
of position partnerships, our licensing Business the global President will function identify footprint. and Jim a During we to of alliances portfolio industry to James development quarter, Planning. to our potential efforts Strategic and our Executive the expand XX-year veteran, opportunities Loerop who evaluate third advance Development and oversee newly is business Vice and created global and appointed commercial acquisitions,
Clinical teams position and and Affairs, regulatory Vice global clinical our We the also Mira processes. Leiwant and recently Quality, and health submissions as our international oversee and created President U.S. Regulatory Mira new appointed with to Affairs. quality well of as governmental strategy, will authorities interactions regulatory newly of
Slide Please increasingly pace role will and in turn X. the we regulatory development, become as We submissions, ultimately believe Mira's to coming coming accelerate product product launches number of important the years.
in very during out hybrid our the are force of build the pleased the sales commercial U.S. We quarter. internal third have completed to
onboarded the President the Steve skilled regional domestic Goldy. sales to of northeast, central southeast Vice territories, Sales, successfully manage highly west, and X U.S. leadership have directors We our under of all
sales of development. knowledge in will and other experience product joint the therapies extensive have industry restoration and directors The currently support preservation and launch
process a partners additional U.S. of throughout of network are agents, out independent build of local in adding distributor the the regional commenced we addition, and In the and
noted market economic the of to turn are of our and As will I ability the calls, and our X. model favorable we our Please this have hybrid with direct take with future control prior sight confident strategy. commercial to number Slide new earnings greater more Anika to commercial on provide in line results,
Turning the TACTOSET now to September, second launch the of In in P, the commenced soft products. U.S. we
delivered under a As surgically launched a TACTOSET model. reminder, first is therapy procedures and hybrid repair for the therapy our commercial bone
of TACTOSET use successfully ease the and The positive in August, of continue and the to first efficiency. from completed procedure therapy's surgical community procedural regarding feedback receive we was physician
call at the full during Evolving track at on discussed to We Orthopedic OSET, in is quarter. or As and as conferences Vegas held Summit we've the multiple showcased execute previously, we remain Conference being Las commercial which TACTOSET launch scale medical this XXXX it we December. Techniques have the
to to As of treatment repair eligible $XXX growth approximately with for million $XXX bone attractive near-term bone we opportunity the represents previously for for million an knee. Anika. the have annually XXX,XXX voids stated, market be bone defects TACTOSET U.S. we estimate people other and
distributor Our number by near-term of OSET surgical clear: crystal in in goal goals full launch X for this centers onboard the program December; complete being XX of year. with additional the agents scale Number the end this two, are at one,
blocks initiatives of number U.S. market end important by turn distributor I for XX Vice are you to and agents and These ask grow would to sales, penetration are in plan to XXXX. of revenue building President XXXX the now to again once Slide led We growth please thereafter. our X. by
product model, U.S. expect and in our will launch be rotator the cuff We under hybrid our therapy progressing currently the development commercial as planned. product second is
is highly is have million regenerative $XXX growing previously unique million repair therapy the to we opportunity As noted, rotator believe to annually. therapy for and estimate complementary U.S. cuff we this portfolio, we market that $XXX Anika's
that quarter, instrument late to XXXX the instrumentation refine the half in we our a to of this FDA began and R&D. XXXX third XXX(k) in to submit President plan therapy continued We the led In will we the complete the and early first to prototype Vice application the time design for and of by design XX% XXXX surgical of very this has CINGAL our CINGAL revenue to in towards Europe. XX% in confidence The advance approval U.S. well regulatory turn in quarter growth to Canada further year-to-date. increased to frame. X. CINGAL and CINGAL the Slide year-over-year Please quarter third decision the International our number market. reinforced and perform continued across continues from anticipate
XX needed currently success we discussed to to CINGAL trial will that a approval. data generate to study confirm are to last ultimately the our a in trial working pilot be study triamcinolone finalizing first of sites process study quarter, commence FDA the we saline receive patients of on to We track support in initiate III probability As either the pilot increase our and Phase hexacetonide enroll remain design, and pilot is the or in the the trial newly we steroid protocol. randomized are approximately XXX U.S. XXXX, across placebo. CINGAL, of designed to pilot expected in clinical half The
reminder, a III are there compared this prior differentiators study. X different in Phase revised XX-XX key the protocol to As
The patient will is the to needed a generate Phase first arm; data enable the selection ideal of enrollment subsequent much us hexacetonide, larger profile. the in is triamcinolone elements addition the a is believe of steroid TH the III the third these placebo of inclusion the the patient criteria arm; target second We a meaning arm, to the and modification trial.
we complete. pilot X billion. delay study Despite to opportunity, to time approximately in $X market, CINGAL's approximately we We expect remain be confident the estimated to in that have continue will market U.S. take which to the year
number now to XX. Slide Turning
of trial HYALOFAST We approval. are focused on accelerating the U.S. ongoing for in Phase the enrollment III pace
percentile the During the outside currently the implement complete Patient by adding XX last enrollment the following and currently quarter process end the changes XXXX. is of range, of quarter, U.S. we approved continue sites are new X Europe. enrollment and in protocol to we amendment the to the expect and in
continue new advance forward benefiting Affairs of Clinical Quality, Regulatory look of Vice we and leadership the trial. Leiwant, as President we our Additionally, to the to Mira Affairs, from
orthopedic high see in very than symposia, among regenerative be Joint patients U.S. estimate in We surgeons level Vancouver, of Canada. significant represents Congress held for of which a we educational conservatively XXXX Preservation innovative and participated held to Over on Regeneration billion. Society, and Cartilage recently another more enthusiasm HYALOFAST $X.X World International XX to symposia market HYALOFAST at continue for the this therapy. physicians we an the opportunity, the and surgeons
progress our our business third with the execute quarter our across collectively growth very strategy. We organization as continued results are we pleased and we are making
over in call I results will now to turn our third quarter review Sylvia back financial greater Sylvia? detail. to the
